Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).

MLA

Watson, S., et al. “Oxaliplatin, 5-Fluorouracil and Nab-Paclitaxel as Perioperative Regimen in Patients with Resectable Gastric Adenocarcinoma: A GERCOR Phase II Study (FOXAGAST).” European Journal of Cancer (Oxford, England : 1990), vol. 107, Jan. 2019, pp. 46–52. EBSCOhost, https://doi.org/10.1016/j.ejca.2018.11.006.

APA

Watson, S., de la Fouchardière, C., Kim, S., Cohen, R., Bachet, J. B., Tournigand, C., Ferraz, J. M., Lefevre, M., Colin, D., Svrcek, M., Meurisse, A., & Louvet, C. (2019). Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). European Journal of Cancer (Oxford, England : 1990), 107, 46–52. https://doi.org/10.1016/j.ejca.2018.11.006

Chicago

Watson, S, C de la Fouchardière, S Kim, R Cohen, J B Bachet, C Tournigand, J M Ferraz, et al. 2019. “Oxaliplatin, 5-Fluorouracil and Nab-Paclitaxel as Perioperative Regimen in Patients with Resectable Gastric Adenocarcinoma: A GERCOR Phase II Study (FOXAGAST).” European Journal of Cancer (Oxford, England : 1990) 107 (January): 46–52. doi:10.1016/j.ejca.2018.11.006.